Hellebrigenol
CAS No. 508-79-2
Hellebrigenol( —— )
Catalog No. M31726 CAS No. 508-79-2
Hellebrigenol shows cytotoxicity against HepG2 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 297 | In Stock |
|
| 10MG | 468 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHellebrigenol
-
NoteResearch use only, not for human use.
-
Brief DescriptionHellebrigenol shows cytotoxicity against HepG2 cells.
-
DescriptionHellebrigenol shows cytotoxicity against HepG2 cells.
-
In VitroHellebrigenol shows cytotoxicity against HepG2 cells with an IC50 of 56.581 ng/mL.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number508-79-2
-
Formula Weight418.52
-
Molecular FormulaC24H34O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Neuromedin S (rat)
Potent, endogenous neuromedin U receptor agonist (EC50 values are 65 and 91 pM at NMU1 and NMU2 respectively). Induces phase shifts in the circadian rhythm of locomotor activity following i.c.v. administration. Potent endogenous anorexigenic peptide.
-
Florfenicol amine
Florfenicol amine is a metabolite of Florfenicol. Florfenicol, a veterinary antibiotic, can be used in aquaculture to control susceptible bacterial diseases.
-
Chitinase, Serratia ...
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer).
Cart
sales@molnova.com